Payment of 4712 shares by Dustin Sjuts of Revance subject to Rule 16b-3
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
About 52% of Revance Therapeutics,'s investor base is interested to short. The analysis of current outlook of investing in Revance Therapeutics, suggests that many traders are impartial regarding Revance Therapeutics,'s prospects. The current market sentiment, together with Revance Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Revance Therapeutics, stock news signals to limit their universe of possible portfolio assets.
Revance |
Filed transaction by Revance Therapeutics Inc officer. Payment of exercise price or tax liability by delivering or withholding securities
Read at macroaxis.com
Revance Therapeutics, Fundamental Analysis
We analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Revance Therapeutics, is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Revance Therapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Revance Therapeutics, stock to make a market-neutral strategy. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics with similar companies.
Peers
Revance Therapeutics, Related Equities
| ETNB | 89bio | 11.72 | ||||
| IMCR | Immunocore Holdings | 2.24 | ||||
| APLS | Apellis Pharmaceuticals | 2.19 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.57 | ||||
| DMAC | DiaMedica Therapeutics | 1.47 | ||||
| PLRX | Pliant Therapeutics | 1.34 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.03 | ||||
| DAWN | Day One | 0.86 | ||||
| VTYX | Ventyx Biosciences | 0.82 | ||||
| STOK | Stoke Therapeutics | 0.68 | ||||
| AKRO | Akero Therapeutics | 0.67 | ||||
| TERN | Terns Pharmaceuticals | 0.65 | ||||
| NUVL | Nuvalent | 0.42 | ||||
| ACLX | Arcellx | 2.28 | ||||
| BPMC | Blueprint Medicines | 3.60 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |